Travoprost

• CAS: 157283-68-6
• Catalog Number: ACM157283686
• Category: Other Products
• Molecular Weight: 500.55
• Molecular Formula: C₂₆H₃₅F₃O₆
• Synonyms: (+/-)-16-(M-TRIFLUOROMETHYLPHENOXY)TETRANORPROSTAGLANDIN F2;15(S)-FLU-IPR;15(S)-FLUPROSTENOL ISOPROPYL ESTER;(+)-9ALPHA,11ALPHA,15R-TRIHYDROXY-16-(3-(TRIFLUOROMETHYL)PHENOXY)-17,18,19,20-TETRANOR-PROSTA-5Z,13E-DIEN-1-OIC ACID, ISOPROPYL ESTER;9ALPHA,11ALPHA,15S-TRIHYDROXY-16(3-(TRIFLUOROMETHYL)PHENOXY)-17,18,19,20-TETRANOR-PROSTA-5Z,13E-DIEN-1-OIC ACID, ISOPROPYL ESTER;(+)-FLUPROSTENOL ISOPROPYL ESTER;FLUPROSTENOL ISOPROPYL ESTER;FLU-IPR
• Flash Point: 17°C
• Appearance: ethanol solution
• Hazard Statements: F,Xi
• Safety Description: 16-26-36-7

Custom Q&A

What is the molecular formula of travoprost?

The molecular formula of travoprost is C26H35F3O6.

What is the molecular weight of travoprost?

The molecular weight of travoprost is 500.5 g/mol.

What is the IUPAC name of travoprost?

The IUPAC name of travoprost is propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate.

What is the InChIKey of travoprost?

The InChIKey of travoprost is MKPLKVHSHYCHOC-AHTXBMBWSA-N.

What are the synonyms of travoprost?

The synonyms of travoprost include Travatan, Travatan Z, Izba, and more.

What is the CAS number of travoprost?

The CAS number of travoprost is 157283-68-6.

What is the approved use of travoprost?

Travoprost is approved for controlling the progression of open-angle glaucoma and ocular hypertension by reducing intraocular pressure.

Does travoprost contain benzalkonium chloride?

No, travoprost is the only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain benzalkonium chloride.

What is the role of travoprost?

Travoprost has roles as an antiglaucoma drug, an antihypertensive agent, a prodrug, an ophthalmology drug, and a prostaglandin receptor agonist.

Is travoprost approved for use in pediatric patients?

Yes, travoprost is approved for the decrease of elevated intraocular pressure in pediatric patients aged 2 months to < 18 years with ocular hypertension or pediatric glaucoma.